Infectious disease Santaris is developing a microRNA targeting drug for hepatitis C, miravirsen (SPC3649),[REF] which entered Phase II clinical trials in 2010 [REF].
Rare genetic diseases Santaris has a collaboration with Shire to discover and develop new RNA-based medicines to treat rare genetic disorders [REF].